Post by admin on Jun 24, 2014 6:40:45 GMT -8
Recorded: June 18, 2014
Presenter: Nicholas Vogelzang, MD
Moderator: Tony Crispino
Topic: Dr. Vogelzang discusses results from the phase III CHAARTED study that examined the addition of chemotherapy (docetaxel) to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.
YOU MUST BE A REGISTERED PCAF MEMBER TO VIEW THE WEBINAR OR DOWNLOAD THE DOCUMENTS
To download the PowerPoint file presented during the webinar, and at the ASCO Annual Meeting May 29-June 2, 2014, click HERE
To download the PowerPoint file presented as a discussion supplement during the webinar (and at ASCO 2014), click HERE
To view the webinar online, click HERE. When logging in, please use the password "Vegas."
This webinar was jointly sponsored by PCAF and the Las Vegas chapter of UsToo, and was a live presentation at the UsToo meeting.
About Dr. Vogelzang: Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/coauthored numerous peer-reviewed articles, book chapters and abstracts and has given hundreds of lectures and presentations to his peers. Dr. Vogelzang joined Comprehensive Cancer Centers of Nevada (CCCN) as a medical oncologist in 2009 and he also serves as Chair and Medical Director of the Developmental Therapeutics Committee and Co-Chair of the Genitourinary Committee for US Oncology Research. Prior to joining CCCN, Dr. Vogelzang was Director of the Nevada Cancer Institute from 2004 to 2009. His other prior experience includes serving as the Director of the University of Chicago Cancer Research Center. Dr. Vogelzand is co-author of the CHAARTED study.
CHAARTED study summary: The CHAARTED study enrolled 790 men who would normally have received ADT to treat metastatic prostate cancer that had spread to the bones, lymph nodes, liver, or lungs. In the study, patients were randomized in a 1:1 ratio to receive ADT alone or ADT in combination with the chemotherapy docetaxel. The study found that the benefit of adding 6 doses of chemotherapy to ADT was obvious—the median overall survival was 13.6 months longer in the ADT-plus-docetaxel group compared with the ADT alone group (57.6 vs 44 months; HR = 0.61; P = .0003). Although the study was conducted in an older population, the side effect profile was modest with the combination. Also read the article published in the ASCO Daily News about CHAARTED by clicking HERE.
Presenter: Nicholas Vogelzang, MD
Moderator: Tony Crispino
Topic: Dr. Vogelzang discusses results from the phase III CHAARTED study that examined the addition of chemotherapy (docetaxel) to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.
YOU MUST BE A REGISTERED PCAF MEMBER TO VIEW THE WEBINAR OR DOWNLOAD THE DOCUMENTS
To download the PowerPoint file presented during the webinar, and at the ASCO Annual Meeting May 29-June 2, 2014, click HERE
To download the PowerPoint file presented as a discussion supplement during the webinar (and at ASCO 2014), click HERE
To view the webinar online, click HERE. When logging in, please use the password "Vegas."
This webinar was jointly sponsored by PCAF and the Las Vegas chapter of UsToo, and was a live presentation at the UsToo meeting.
About Dr. Vogelzang: Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/coauthored numerous peer-reviewed articles, book chapters and abstracts and has given hundreds of lectures and presentations to his peers. Dr. Vogelzang joined Comprehensive Cancer Centers of Nevada (CCCN) as a medical oncologist in 2009 and he also serves as Chair and Medical Director of the Developmental Therapeutics Committee and Co-Chair of the Genitourinary Committee for US Oncology Research. Prior to joining CCCN, Dr. Vogelzang was Director of the Nevada Cancer Institute from 2004 to 2009. His other prior experience includes serving as the Director of the University of Chicago Cancer Research Center. Dr. Vogelzand is co-author of the CHAARTED study.
CHAARTED study summary: The CHAARTED study enrolled 790 men who would normally have received ADT to treat metastatic prostate cancer that had spread to the bones, lymph nodes, liver, or lungs. In the study, patients were randomized in a 1:1 ratio to receive ADT alone or ADT in combination with the chemotherapy docetaxel. The study found that the benefit of adding 6 doses of chemotherapy to ADT was obvious—the median overall survival was 13.6 months longer in the ADT-plus-docetaxel group compared with the ADT alone group (57.6 vs 44 months; HR = 0.61; P = .0003). Although the study was conducted in an older population, the side effect profile was modest with the combination. Also read the article published in the ASCO Daily News about CHAARTED by clicking HERE.